Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Genetic and cellular evidence of vascular inflammation in neurofibromin-deficient mice and humans
Elisabeth A. Lasater, … , Simon J. Conway, David A. Ingram Jr.
Elisabeth A. Lasater, … , Simon J. Conway, David A. Ingram Jr.
Published February 15, 2010
Citation Information: J Clin Invest. 2010;120(3):859-870. https://doi.org/10.1172/JCI41443.
View: Text | PDF
Research Article Vascular biology Article has an altmetric score of 6

Genetic and cellular evidence of vascular inflammation in neurofibromin-deficient mice and humans

  • Text
  • PDF
Abstract

Neurofibromatosis type 1 (NF1) results from mutations in the NF1 tumor suppressor gene, which encodes the protein neurofibromin. NF1 patients display diverse clinical manifestations, including vascular disease, which results from neointima formation and vessel occlusion. However, the pathogenesis of NF1 vascular disease remains unclear. Vessel wall homeostasis is maintained by complex interactions between vascular and bone marrow–derived cells (BMDCs), and neurofibromin regulates the function of each cell type. Therefore, utilizing cre/lox techniques and hematopoietic stem cell transplantation to delete 1 allele of Nf1 in endothelial cells, vascular smooth muscle cells, and BMDCs alone, we determined which cell lineage is critical for neointima formation in vivo in mice. Here we demonstrate that heterozygous inactivation of Nf1 in BMDCs alone was necessary and sufficient for neointima formation after vascular injury and provide evidence of vascular inflammation in Nf1+/– mice. Further, analysis of peripheral blood from NF1 patients without overt vascular disease revealed increased concentrations of inflammatory cells and cytokines previously linked to vascular inflammation and vasoocclusive disease. These data provide genetic and cellular evidence of vascular inflammation in NF1 patients and Nf1+/– mice and provide a framework for understanding the pathogenesis of NF1 vasculopathy and potential therapeutic and diagnostic interventions.

Authors

Elisabeth A. Lasater, Fang Li, Waylan K. Bessler, Myka L. Estes, Sasidhar Vemula, Cynthia M. Hingtgen, Mary C. Dinauer, Reuben Kapur, Simon J. Conway, David A. Ingram Jr.

×

Figure 5

In vitro function of Nf1+/– macrophages.

Options: View larger image (or click on image) Download as PowerPoint
In vitro function of Nf1+/– macrophages.
   
(A) Percent monocytes in pe...
(A) Percent monocytes in peripheral blood of WT and Nf1+/– mice. Data represent mean percentage ± SEM, n = 8. *P = 0.02 for Nf1+/– versus WT by Student’s unpaired t test. (B) WT (white bars) and Nf1+/– (black bars) macrophage proliferation in response to M-CSF. Data represent mean cpm ± SEM, n = 4. *P < 0.001 for unstimulated WT versus M-CSF–stimulated WT macrophages; **P < 0.001 for M-CSF–stimulated Nf1+/– versus M-CSF–stimulated WT macrophages, by 1-way ANOVA. (C) WT (white bars) and Nf1+/– (black bars) macrophage haptotaxis in response to M-CSF. Data represent mean number of migrated cells ± SEM, n = 4. *P < 0.001 for unstimulated WT versus M-CSF–stimulated WT macrophages; **P < 0.001 for unstimulated WT versus unstimulated Nf1+/– macrophages; #P < 0.001 for unstimulated Nf1+/– versus M-CSF–stimulated Nf1+/– macrophages, by 1-way ANOVA. (D) WT (white bars) and Nf1+/– (black bars) macrophage adhesion to fibronectin. Data represent mean optical density ± SEM, n = 4. *P < 0.001 for WT versus Nf1+/– macrophages; **P < 0.01 for Nf1+/– macrophages at 60 minutes versus Nf1+/– macrophages at all other time points, by 1-way ANOVA. (E) Macrophage stimulation of WT and Nf1+/– VSMC proliferation. Data represent mean cpm ± SEM, n = 3. *P < 0.05 for Nf1+/– VSMCs cocultured with WT or Nf1+/– macrophages versus WT VSMCs; #P < 0.05 for WT VSMCs cocultured with Nf1+/– macrophages versus WT macrophages and for Nf1+/– VSMCs cocultured with Nf1+/– macrophages versus WT macrophages; †P < 0.05 for WT and Nf1+/– VSMCs treated with MEK inhibitor versus no inhibition, by 1-way ANOVA.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 1 patents
Referenced in 1 Wikipedia pages
44 readers on Mendeley
See more details